Managers / Q1 2022 · view latest →
Roumell Asset Management, LLC
CIK 0001331693 · 2 WISCONSIN CIR, SUITE 700, CHEVY CHASE, MD, 20815 · 301-656-8500
Summary
Roumell Asset Management, LLC reported $62M in U.S.-listed holdings across 19 positions for Q1 2022.
Its largest position, GSIT, represents 12.1% of the portfolio.
Compared with Q4 2021, the fund opened 1 new position and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 70.6% · $44M
- Other · 18.6% · $12M
- ADR · 10.8% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SOFOSONIC FDRY INC | NEW | +405.4K | 405.4K | +$1M | $1M |
| EHTHEHEALTH INC | SOLD OUT | −61.2K | 0 | −$2M | $0 |
| STREAMLINE HEALTH SOLUTIONS | SOLD OUT | −425.0K | 0 | −$625,000 | $0 |
| RICEBRAN TECHNOLOGIES | SOLD OUT | −1.41M | 0 | −$493,000 | $0 |
| KVHIKVH INDS INC | ADDED | +46.9K | 123.1K | +$419,000 | $1M |
| MGNIMAGNITE INC | ADDED | +134.1K | 374.1K | +$741,000 | $5M |
| BCDABIOCARDIA INC | TRIMMED | −401.9K | 536.5K | −$709,000 | $1M |
| COLLPLANT BIOTECHNOLOGIES LT | ADDED | +102.0K | 597.7K | −$1M | $7M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | GSITGSI TECHNOLOGYhistory → | COM | 12.10% | $7M | 1.96M |
| 2 | ENZBENZO BIOCHEM INChistory → | COM | 11.21% | $7M | 2.39M |
| 3 | COLLPLANT BIOTECHNOLOGIES LT | SHS NEW | 11.05% | $7M | 597.7K |
| 4 | OPRAOPERA LTDhistory → | SPONSORED ADS | 8.55% | $5M | 895.1K |
| 5 | MGNIMAGNITE INChistory → | COM | 7.98% | $5M | 374.1K |
| 6 | ALLOT LTD | SHS | 7.58% | $5M | 579.5K |
| 7 | COMSCORE INC | COM | 7.04% | $4M | 1.50M |
| 8 | QUANTUM CORP | COM NEW | 6.06% | $4M | 1.65M |
| 9 | TTITETRA TECHNOLOGIES INC DELhistory → | COM | 5.07% | $3M | 764.3K |
| 10 | ETONETON PHARMACEUTICALS INChistory → | COM | 3.17% | $2M | 449.4K |
| 11 | QUMU CORP | COM | 3.16% | $2M | 1.11M |
| 12 | AMYRIS INC | COM NEW | 3.03% | $2M | 430.0K |
| 13 | CMTLCOMTECH TELECOMMUNICATIONS Chistory → | COM NEW | 2.58% | $2M | 101.6K |
| 14 | SPARK NETWORKS SE | SPONSORED ADS | 2.27% | $1M | 502.8K |
| 15 | NODKNI HLDGS INChistory → | COM | 2.25% | $1M | 82.1K |
| 16 | SOFOSONIC FDRY INChistory → | COM NEW | 2.02% | $1M | 405.4K |
| 17 | KVHIKVH INDS INChistory → | COM | 1.81% | $1M | 123.1K |
| 18 | BCDABIOCARDIA INChistory → | COM | 1.80% | $1M | 536.5K |
| 19 | ARDSARIDIS PHARMACEUTICALS INChistory → | COM | 1.27% | $786,000 | 446.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2024 | $53M | 16 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $53M | 17 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $47M | 15 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $50M | 19 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $51M | 22 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $44M | 20 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $40M | 21 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $46M | 21 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $51M | 21 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $62M | 19 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $75M | 21 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $75M | 17 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $86M | 18 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $69M | 14 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $64M | 16 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $50M | 14 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $41M | 20 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $37M | 22 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $44M | 21 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $42M | 14 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $42M | 18 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $41M | 20 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $48M | 22 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.